- Dogs and cats have endocannabinoid systems with CB1 and CB2 receptors, making them physiologically responsive to cannabinoids — but with important differences from humans.
- A 2018 Cornell University study found significant improvement in pain scores and mobility in dogs with osteoarthritis treated with 2mg/kg CBD twice daily, with minimal adverse effects.
- Dogs have approximately 10 times higher CB1 receptor density in certain brain regions compared to humans, making THC significantly more toxic to them at lower doses relative to body weight.
- A 2019 Colorado State University clinical trial found that 89% of dogs treated with CBD experienced a reduction in seizure frequency compared to placebo.
- Cats metabolize cannabinoids differently from dogs and humans due to hepatic enzyme differences; the evidence base for CBD use in cats is very limited and extreme caution is warranted.
- Pet CBD product quality is highly variable — no FDA regulatory framework exists for veterinary CBD efficacy claims, and third-party testing is not universally required.
- THC ingestion by pets requires immediate veterinary contact; symptoms include ataxia, urinary incontinence, tremors, and in severe cases, coma.
The Endocannabinoid System in Mammals: Shared Biology
The endocannabinoid system (ECS) is not a uniquely human biological system. It is present in all mammals — and indeed in virtually all vertebrates — and plays similar regulatory roles across species. Dogs, cats, horses, and virtually all other mammalian companions have CB1 and CB2 receptors distributed throughout their brains, nervous systems, and peripheral organs, just as humans do. Endogenous cannabinoids (anandamide and 2-arachidonoylglycerol) are produced in their bodies to activate these receptors, regulating pain, inflammation, appetite, sleep, and immune function.
This shared biological architecture is why cannabis compounds, including THC and CBD, produce pharmacological effects in pets — they interact with the same receptor system. However, the fact that both humans and dogs have endocannabinoid systems does not mean they respond identically to exogenous cannabinoids. Species-specific differences in receptor density, distribution, metabolic enzyme expression, and neurological architecture create important distinctions that have direct practical consequences for pet owners.
The most important of these distinctions concerns CB1 receptor density. Research has demonstrated that dogs have a significantly higher density of CB1 receptors in the cerebellum and brainstem than humans. These are the brain regions responsible for coordination, balance, and basic vital functions. This elevated CB1 expression in neurologically critical regions is believed to explain why dogs are so much more sensitive to THC’s toxic effects than humans. Understanding this fundamental difference is essential for any pet owner navigating cannabis use in a household with animals. Our broader how cannabis works explainer covers the ECS in detail.
CBD vs THC: Very Different Profiles in Animals
The stark contrast between CBD’s safety profile and THC’s toxicity in dogs is the foundational distinction that structures all pet cannabis guidance. CBD does not produce the intoxicating effects of THC because it does not function as a direct CB1 receptor agonist. Instead, CBD modulates the ECS through multiple indirect pathways, produces anti-inflammatory and analgesic effects, and is cleared through the liver without the potent neurological effects that make THC dangerous at higher doses. The available veterinary research consistently shows CBD to be well-tolerated in dogs at therapeutic doses.
THC, by contrast, produces dose-dependent toxicity in dogs that can escalate from mild disorientation at low doses to coma and death at extremely high doses (though fatalities are rare and typically involve very small dogs consuming large amounts of concentrated THC products). The increased popularity of high-potency cannabis edibles, infused chocolates, and concentrated extracts in legal-state households has driven a significant increase in accidental pet THC ingestion cases reported to veterinary emergency services. The American Society for the Prevention of Cruelty to Animals (ASPCA) Poison Control Center reported a dramatic increase in cannabis-related pet exposure calls following state legalizations.
Veterinary Research: What Studies Show
Veterinary cannabis research remains limited compared to human clinical research, but several landmark studies have established a meaningful evidence base for CBD in dogs specifically. These studies have been conducted at major academic veterinary institutions and published in peer-reviewed journals.
Cornell University Arthritis Study (2018)
The most widely cited study on CBD for pets was conducted by researchers at Cornell University College of Veterinary Medicine and published in the journal Frontiers in Veterinary Science. The randomized, double-blind, placebo-controlled crossover study enrolled 22 dogs with confirmed osteoarthritis. Dogs received either CBD oil at 2mg/kg twice daily or a placebo, with a washout period before crossing to the other arm.
The results were significant: 80% of dogs in the CBD group showed clinically meaningful improvement on validated pain and mobility scales (the Canine Brief Pain Inventory and Hudson Activity Scale). Owners reported decreased pain and increased activity. Critically, adverse effects were minimal — the primary finding was a mild, transient increase in serum alkaline phosphatase (ALP) liver enzyme levels in some CBD-treated dogs. This liver enzyme elevation did not progress to clinical liver disease in the study period but suggests that dogs on CBD should have periodic liver function monitoring, particularly with long-term use.
Colorado State University Epilepsy Trial (2019)
Researchers at Colorado State University College of Veterinary Medicine and Biomedical Sciences conducted a randomized, blinded, crossover trial of CBD in dogs with idiopathic (unexplained origin) epilepsy. Sixteen client-owned dogs with uncontrolled seizures were randomized to receive either CBD (2.5mg/kg twice daily added to current anti-epileptic medication) or placebo for 12 weeks, then crossed over.
The study found that 89% of dogs receiving CBD experienced a reduction in seizure frequency compared to placebo. While the authors called for larger studies to confirm these findings, the signal was strong enough that CBD is now frequently discussed as an adjunct treatment for refractory canine epilepsy. This mirrors the human experience with FDA-approved CBD medication Epidiolex, which was specifically approved for rare childhood epilepsy syndromes. For context on how CBD interacts with seizure medications in humans, see our drug interactions explainer.
Safe CBD Dosing for Dogs by Weight
Based on the available research and veterinary guidance, the following dosing framework is widely cited. Note that these are general guidelines; individual dogs may respond differently, and products vary in actual CBD concentration despite label claims. Always verify product concentration with third-party certificate of analysis (COA) before dosing.
| Dog Weight | Starting Dose (CBD) | Maintenance Dose (CBD) | Daily Frequency |
|---|---|---|---|
| Under 10 lbs (4.5kg) | 1–2 mg CBD | 2–4 mg CBD | 1–2x per day |
| 10–25 lbs (4.5–11kg) | 2–5 mg CBD | 5–10 mg CBD | 2x per day |
| 25–50 lbs (11–23kg) | 5–10 mg CBD | 10–20 mg CBD | 2x per day |
| 50–100 lbs (23–45kg) | 10–15 mg CBD | 15–30 mg CBD | 2x per day |
| Over 100 lbs (45kg+) | 15–20 mg CBD | 20–40 mg CBD | 2x per day |
These guidelines are based on the 2mg/kg body weight dose used in the Cornell study. Always use products with verified CBD content via third-party COA. Monitor liver enzymes (ALT, ALP) every 3–6 months with ongoing use. Consult your veterinarian before starting any CBD regimen, particularly if your pet takes medications.
Veterinary-Grade CBD vs Human CBD Products
Human CBD products are not necessarily unsafe for dogs, but there are important considerations. Never use products containing xylitol (an artificial sweetener toxic to dogs commonly used in human gummies and edibles). Verify that any product used contains no THC or only certified trace amounts (<0.1%). Veterinary-formulated CBD products typically use pet-appropriate carriers (hemp seed oil, coconut oil) and are dosed more precisely for weight-based administration. Some carry NASC (National Animal Supplement Council) quality seal, indicating adherence to manufacturing standards.
Human full-spectrum CBD products, while often high quality, carry a small risk of containing trace THC that, while negligible for humans, could cause effects in a small dog. Broad-spectrum or isolate CBD products are safer choices for pets precisely because they eliminate THC entirely.
THC Toxicity in Pets: Symptoms and Emergency Response
THC ingestion is a veterinary emergency when significant amounts are involved. As cannabis products become more potent and more accessible in legal households, accidental pet ingestion is an increasingly common emergency scenario. Pet owners in cannabis-legal households should know the signs of THC toxicity and have a response plan.
Signs of THC Toxicity in Dogs
Symptoms of cannabis toxicity in dogs typically appear within 30–90 minutes of ingestion and can last 18–36 hours depending on the dose:
- Ataxia (loss of coordination, stumbling, swaying) — one of the most characteristic signs
- Urinary incontinence — urine dribbling, loss of bladder control
- Dilated pupils and glazed, “stoned” appearance
- Extreme lethargy or inability to stand
- Vomiting (particularly shortly after ingestion)
- Hypersalivation (drooling excessively)
- Bradycardia or tachycardia (abnormal heart rate)
- Tremors or muscle twitching at higher doses
- Coma in severe overdose (rare but possible with concentrated products)
Emergency Response Protocol
Step 1: Stay calm. Most dogs recover fully from cannabis ingestion with supportive care. Step 2: Contact your veterinarian or animal emergency clinic immediately. Provide the estimated amount of THC consumed, the form (flower, edible, concentrate), and the time of ingestion. Step 3: Contact ASPCA Animal Poison Control Center: (888) 426-4435 (US, 24/7) if your vet is unavailable. Step 4: Do not induce vomiting unless specifically directed by a veterinarian. Step 5: Keep your pet warm, calm, and prevent them from injuring themselves due to disorientation.
At the veterinary clinic, treatment is supportive: IV fluids, anti-nausea medication, warmth, and monitoring. Most dogs recover within 24–36 hours. Being honest with your veterinarian about cannabis exposure is critical — vets are not legally required to report it, and accurate information is essential for appropriate treatment.
Cats and Cannabis: Extra Caution Required
While dogs are the primary subject of pet cannabis research, many owners are interested in CBD for cats with conditions including anxiety, arthritis pain, and inflammatory bowel disease. The honest answer is that the evidence base for cats is substantially weaker than for dogs, and feline physiology warrants additional caution.
Cats have deficiencies in certain hepatic glucuronidation enzymes that are important for metabolizing many substances, including some drugs, phenols, and potentially cannabinoids. This is why cats are famously sensitive to drugs that humans and dogs tolerate well — aspirin toxicity in cats is a well-known veterinary example. Whether this metabolic difference significantly affects CBD clearance and safety is not yet well-established in peer-reviewed research. The available small-scale studies suggest CBD is generally tolerated in cats at low doses, but with more variability in adverse effects than seen in dogs.
THC toxicity in cats presents similarly to dogs (ataxia, hypersalivation, dilated pupils, vocalization) and requires the same emergency veterinary response. The ASPCA and most veterinary toxicologists consider THC ingestion in cats to be more unpredictable than in dogs, partly due to metabolic differences.
WATCH: CBD for Pets — Veterinary Perspectives